Contributions
Abstract: EP1192
Type: E-Poster Presentation
Session title: Quality of life, palliative care, ethics and health economics
Background
Patient preferences have become an important focus for inclusion in the drug development, regulatory, and reimbursement process for multiple myeloma (MM) treatments (Postmus et al, 2018; Fifer et al, 2020). Over the last decade there has been a rapid development of new medicines for MM, all with varying safety and efficacy profiles. Therefore, the need for a clear and standardized methodology for collection of patient preference data is important.
Aims
This study aimed to understand which characteristics of treatment MM patients find most important and should be included as attributes in a subsequent (quantitative) preference survey.
Methods
This research incorporates a literature review and qualitative discussions with patients to formulate attributes for inclusion in a subsequent quantitative patient preference survey. This qualitative study involved: i) a scoping literature review, ii) discussions with MM patients (n=24) in Belgium, Finland, Romania, and Spain using Nominal Group Technique (NGT), and iii) a qualitative thematic analysis with multi-stakeholder discussions.
Results
After completion of the literature review, a patient consensus on MM treatment attributes was reached using NGT. Thematic analysis generated the following treatment attributes for inclusion in the subsequent quantitative patient preference survey: i) life expectancy, ii) life-threatening side-effects (such as the development of another cancer), iii) treatment response (i.e., a reduction of cancer signs), iv) nerve or bone problems affecting movement (such as fractures), v) thinking problems (such as concentration problems), vi) increased susceptibility to infections, vii) reduced energy, viii) pain (such as bone pain), ix) emotional problems (such as mood changes), x) eating and digestive problems (such as incontinence), and xi) vision problems (such as blurred vision).
Conclusion
Obtaining patient insights for inclusion in subsequent quantitative preference studies requires several steps. This study highlights the importance of the incorporation of the qualitative portion of a patient preference study, to ensure sensitive and appropriate attribute selection. This study illustrates that patients focus not only on treatment efficacy, but also value a reduction of MM-related symptoms and side effects.
Keyword(s): Multiple myeloma, Qualitative
Abstract: EP1192
Type: E-Poster Presentation
Session title: Quality of life, palliative care, ethics and health economics
Background
Patient preferences have become an important focus for inclusion in the drug development, regulatory, and reimbursement process for multiple myeloma (MM) treatments (Postmus et al, 2018; Fifer et al, 2020). Over the last decade there has been a rapid development of new medicines for MM, all with varying safety and efficacy profiles. Therefore, the need for a clear and standardized methodology for collection of patient preference data is important.
Aims
This study aimed to understand which characteristics of treatment MM patients find most important and should be included as attributes in a subsequent (quantitative) preference survey.
Methods
This research incorporates a literature review and qualitative discussions with patients to formulate attributes for inclusion in a subsequent quantitative patient preference survey. This qualitative study involved: i) a scoping literature review, ii) discussions with MM patients (n=24) in Belgium, Finland, Romania, and Spain using Nominal Group Technique (NGT), and iii) a qualitative thematic analysis with multi-stakeholder discussions.
Results
After completion of the literature review, a patient consensus on MM treatment attributes was reached using NGT. Thematic analysis generated the following treatment attributes for inclusion in the subsequent quantitative patient preference survey: i) life expectancy, ii) life-threatening side-effects (such as the development of another cancer), iii) treatment response (i.e., a reduction of cancer signs), iv) nerve or bone problems affecting movement (such as fractures), v) thinking problems (such as concentration problems), vi) increased susceptibility to infections, vii) reduced energy, viii) pain (such as bone pain), ix) emotional problems (such as mood changes), x) eating and digestive problems (such as incontinence), and xi) vision problems (such as blurred vision).
Conclusion
Obtaining patient insights for inclusion in subsequent quantitative preference studies requires several steps. This study highlights the importance of the incorporation of the qualitative portion of a patient preference study, to ensure sensitive and appropriate attribute selection. This study illustrates that patients focus not only on treatment efficacy, but also value a reduction of MM-related symptoms and side effects.
Keyword(s): Multiple myeloma, Qualitative